The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics

Asthma Clinical Trial

Official title:

The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00625989
• Other study ID #: sputdend08
• Secondary ID: BDUA2008
• Status: Completed
• Phase: Early Phase 1
• Start date: February 2008
• Est. completion date: December 2008

Study information

• Verified date: April 2015
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Summary:

A picture is emerging of dendritic cells migrating through the blood to the airways following allergen inhalation in atopic asthmatics. Although the Koh and McCarthy articles present novel findings, both do not provide a comprehensive view of sputum DCs following allergen challenge. Therefore, the proposed study will examine the kinetics of mDCs and pDCs in the induced sputum of atopic asthmatics following inhalation of allergen.

Hypothesis:

Following allergen challenge, sputum myeloid and plasmacytoid DCs will migrate into the airway lumen in atopic asthmatics during the timeframe of the late asthmatic response.

Objective:

The objective of this study is to examine the kinetics of dendritic cells in induced sputum following allergen challenge in atopic asthmatic subjects.

Description:

Subjects will be put through two study periods. Each study period will consist of four visits and will be separated by 2-4 weeks. On the first visit, subjects will undergo screening procedures, including complete history and physical examination. In addition, methacholine inhalation challenge and skin-prick testing will be preformed to assess airway hyper-responsiveness and determine atopic status respectively. Lastly, sputum will be induced before challenge (0 hrs) and peripheral blood will be collected. On the second visit, subjects will inhale diluent or allergen and sputum will be collected 7 hours following inhalation challenge. Next, on the third visit, subjects will return 24 hours following inhalation challenge and sputum will be induced. On the final visit, subjects will return 72 hours following inhalation challenge and sputum will be collected, along with peripheral blood.

Before the next study period begins, there will be a washout period of 2-4 weeks. On the first visit of the second study period, a methacholine challenge will be performed to ensure the return of PC20 to within one doubling dose of baseline values. Also, sputum will be induced before challenge (0hrs) and peripheral blood will be collected. On the second visit, subjects will inhale diluent or allergen and sputum will be collected 7hrs following inhalation challenge. Next, on the third visit, subjects will return 24 hours following inhalation challenge and sputum will be induced. On the final visit, subjects will return 72 hours following inhalation challenge and sputum will be collected, along with peripheral blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 2008
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Mild atopic asthmatics, presently well controlled on ß2-agonists.

• Non-smokers.

• Baseline FEV1 more than 70% of predicted normal.

Exclusion Criteria:

• Airway infection during the last 4 weeks.

• Exacerbation during the last 4 weeks.

• Inhaled or oral steroids during the last 4 weeks.

• Antihistamines during the last 48 hours.

• Asthma medication other than inhaled and/or oral ß2-agonists during the last 4 weeks.

• Pregnant women.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Aeroallergen

Locations

Country	Name	City	State
Canada	McMaster University	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells	Flow-cytometric acquisitions were used to determine the percentage of each type of mononuclear cell. These percentages were multiplied by the number of sputum mononuclear cells calculated by using total and differential cell counts of the sputum sample.	24 hrs
Primary	The Primary Outcome Measure for This Study is the Number of Sputum Plasmacytoid Dendritic Cells	Flow-cytometric acquisitions were used to determine the percentage of each type of mononuclear cell. These percentages were multiplied by the number of sputum mononuclear cells calculated by using total and differential cell counts of the sputum sample.	24 hrs
Secondary	The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant.		Before inhalation (0hrs)
Secondary	The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant		7 hrs
Secondary	The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant		24 hrs
Secondary	The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant		72 hrs